Reinforcing effects of synthetic cathinones in rhesus monkeys: Dose-response and behavioral economic analyses.
Alkaloids
/ administration & dosage
Animals
Behavior, Animal
/ drug effects
Benzodioxoles
/ administration & dosage
Central Nervous System Stimulants
/ administration & dosage
Cocaine
/ administration & dosage
Dopamine Plasma Membrane Transport Proteins
/ metabolism
Dose-Response Relationship, Drug
Female
Macaca mulatta
Male
Methamphetamine
/ administration & dosage
N-Methyl-3,4-methylenedioxyamphetamine
/ administration & dosage
Pentanones
/ administration & dosage
Protein Binding
Pyrrolidines
/ administration & dosage
Reinforcement, Psychology
Self Administration
Serotonin Plasma Membrane Transport Proteins
/ metabolism
Synthetic Drugs
/ administration & dosage
Synthetic Cathinone
Behavioral economics
Cathinone
Rhesus monkeys
Self-administration
Journal
Pharmacology, biochemistry, and behavior
ISSN: 1873-5177
Titre abrégé: Pharmacol Biochem Behav
Pays: United States
ID NLM: 0367050
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
30
08
2020
revised:
31
12
2020
accepted:
31
12
2020
pubmed:
15
1
2021
medline:
11
8
2021
entrez:
14
1
2021
Statut:
ppublish
Résumé
The abuse of synthetic cathinones ("bath salts") with psychomotor stimulant and/or entactogenic properties emerged as a public health concern when they were introduced as "legal" alternatives to drugs of abuse such as cocaine or MDMA. In this study, experiments were conducted in nonhuman primates to examine how differences in transporter selectivity might impact the reinforcing effects of synthetic cathinones. Rhesus monkeys (N = 5) were trained to respond for intravenous injections under a fixed-ratio (FR) 30, timeout 60-s schedule of reinforcement. The reinforcing effects of selected cathinones (e.g., MDPV, αPVP, MCAT, and methylone) with a range of pharmacological effects at dopamine and serotonin transporters were compared to cocaine and MDMA using dose-response analysis under a simple FR schedule and behavioral economic procedures that generated demand curves for two doses of each drug. Results show that one or more doses of all drugs were readily self-administered in each subject and, excepting MDMA (21 injections/session), peak levels of self-administration were similar across drugs (between 30 and 40 injections/session). Demand elasticity for the peak and the peak + 1/2-log dose of each drug did not significantly differ, and when data for the two doses were averaged for each drug, the following rank-order of reinforcing strength emerged: cocaine > MCAT = MDPV = methylone > αPVP = MDMA. These results indicate that the reinforcing strength of synthetic cathinones are not related to their selectivity in binding dopamine or serotonin transporter sites.
Identifiants
pubmed: 33444603
pii: S0091-3057(21)00010-1
doi: 10.1016/j.pbb.2021.173112
pmc: PMC7938610
mid: NIHMS1667615
pii:
doi:
Substances chimiques
Alkaloids
0
Benzodioxoles
0
Central Nervous System Stimulants
0
Dopamine Plasma Membrane Transport Proteins
0
Pentanones
0
Pyrrolidines
0
Serotonin Plasma Membrane Transport Proteins
0
Synthetic Drugs
0
Methamphetamine
44RAL3456C
cathinone
540EI4406J
1-phenyl-2-(1-pyrrolidinyl)-1-pentanone
767K3AWA4R
Cocaine
I5Y540LHVR
N-Methyl-3,4-methylenedioxyamphetamine
KE1SEN21RM
methylone
L4I4B1R01F
Synthetic Cathinone
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
173112Subventions
Organisme : NIDA NIH HHS
ID : K01 DA039306
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA002519
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA048150
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Références
Behav Processes. 1997 Feb;39(2):177-85
pubmed: 24896964
J Pharmacol Exp Ther. 2017 Apr;361(1):181-189
pubmed: 28179474
Neuropharmacology. 2014 Dec;87:206-13
pubmed: 24594476
Br J Pharmacol. 2013 Jan;168(2):458-70
pubmed: 22897747
Neuroreport. 1997 Apr 14;8(6):1347-51
pubmed: 9172133
J Pharmacol Exp Ther. 1977 Nov;203(2):303-9
pubmed: 409837
Science. 1987 Sep 4;237(4819):1219-23
pubmed: 2820058
Psychopharmacology (Berl). 2003 Aug;169(1):21-7
pubmed: 12774185
Neuropsychopharmacology. 2012 Apr;37(5):1192-203
pubmed: 22169943
Eur J Pharmacol. 2007 Mar 22;559(2-3):132-7
pubmed: 17223101
Eur J Neurosci. 2007 Dec;26(11):3229-36
pubmed: 18005064
Neuropsychopharmacology. 2013 Mar;38(4):563-73
pubmed: 23212455
Clin Toxicol (Phila). 2014 Aug;52(7):651-8
pubmed: 25089721
Psychol Rev. 2008 Jan;115(1):186-98
pubmed: 18211190
Psychopharmacology (Berl). 1989;97(2):179-82
pubmed: 2498926
QJM. 2010 Jul;103(7):489-93
pubmed: 20413562
Clin Toxicol (Phila). 2011 Jul;49(6):499-505
pubmed: 21824061
Neuropharmacology. 2018 May 1;133:171-180
pubmed: 29378213
Forensic Sci Int. 2013 Dec 10;233(1-3):416-22
pubmed: 24314548
Psychopharmacology (Berl). 2019 Mar;236(3):1031-1041
pubmed: 30267131
Life Sci. 1990;47(17):1501-10
pubmed: 2250566
Addict Biol. 2016 Mar;21(2):339-47
pubmed: 25475011
Eur J Pharmacol. 2003 Oct 31;479(1-3):23-40
pubmed: 14612135
Drug Test Anal. 2013 Jun;5(6):420-9
pubmed: 22549997
Addict Biol. 2014 Sep;19(5):874-84
pubmed: 23763615
Psychopharmacology (Berl). 2019 Dec;236(12):3677-3685
pubmed: 31346629
Drug Alcohol Depend. 2013 Sep 1;132(1-2):1-12
pubmed: 23916320
J Pharmacol Exp Ther. 1989 Oct;251(1):150-5
pubmed: 2529365
J Exp Anal Behav. 1988 Nov;50(3):419-40
pubmed: 3209958
J Pharmacol Exp Ther. 1989 Mar;248(3):1010-7
pubmed: 2703961
Br J Pharmacol. 2015 Feb;172(3):883-94
pubmed: 25255824
J Pharmacol Exp Ther. 2017 Jan;360(1):33-47
pubmed: 27799294
Ann N Y Acad Sci. 2006 Aug;1074:245-60
pubmed: 17105921
Br J Pharmacol. 2012 Sep;167(2):407-20
pubmed: 22509960
Neuropharmacology. 2015 May;92:90-7
pubmed: 25600245
Psychopharmacology (Berl). 2017 Feb;234(4):589-598
pubmed: 27896377
Biochem Pharmacol. 2013 Jun 15;85(12):1803-15
pubmed: 23583454
J Pharmacol Exp Ther. 2007 Feb;320(2):627-36
pubmed: 17071819
Life Sci. 2014 Feb 27;97(1):2-8
pubmed: 23911668
Psychopharmacology (Berl). 2017 Dec;234(23-24):3455-3465
pubmed: 28889212
J Pharmacol Exp Ther. 2005 May;313(2):848-54
pubmed: 15677348
Ciba Found Symp. 1992;166:149-61; discussion 161-4
pubmed: 1638910
Psychopharmacology (Berl). 2007 Nov;194(4):563-72
pubmed: 17628791
Psychopharmacology (Berl). 2015 Aug;232(16):3045-55
pubmed: 25925780
J Exp Anal Behav. 2006 Jan;85(1):73-93
pubmed: 16602377
Int J Neuropsychopharmacol. 2014 Dec 07;18(6):
pubmed: 25522432
Neuropharmacology. 2004;47 Suppl 1:3-13
pubmed: 15464121
Psychopharmacology (Berl). 2016 Jul;233(13):2451-8
pubmed: 27076210
Science. 1974 Sep 20;185(4156):1067-9
pubmed: 4212011
Drug Alcohol Depend. 2013 Dec 1;133(2):593-9
pubmed: 23998378
Pharmacol Biochem Behav. 2006 Jun;84(2):337-43
pubmed: 16828855
Neuropsychopharmacology. 2018 Nov;43(12):2399-2407
pubmed: 30305739
Br J Clin Pharmacol. 2000 Feb;49(2):104-9
pubmed: 10671903
J Pharmacol Exp Ther. 2003 Oct;307(1):356-66
pubmed: 12954808
Behav Pharmacol. 2017 Oct;28(7):578-581
pubmed: 28570297
Hum Psychopharmacol. 2013 Jul;28(4):341-4
pubmed: 23881882
Behav Pharmacol. 2017 Oct;28(7):586-589
pubmed: 28704276
Neuropsychopharmacology. 2018 Mar;43(4):761-769
pubmed: 28677665